Movement Alert|Intel Falls 4.82% in Regular Trading, Massive Capex Hike Sparks Valuation Debate Despite Record Q2 Revenue Growth

Market Focus
Jul 28

On July 28, Intel fell 4.82% in regular trading, trading at $87.25/share, with turnover of $745 million. The stock extended its post-earnings decline as investors weighed record revenue growth against a sharply higher capital expenditure trajectory.

On the news front, Intel previously reported Q2 revenue of $16.1 billion, up 25% year-over-year — the strongest quarterly growth in nearly fifteen years — with adjusted EPS of $0.42, double market expectations. Q3 revenue guidance of $15.8 billion to $16.8 billion also far exceeded consensus of $15.1 billion. However, the company raised full-year capital expenditure from $15 billion to $20 billion, with expectations of approximately $30 billion next year, while adjusted free cash flow remains negative. Wedbush noted that improving fundamentals remain constrained by valuation, maintaining a neutral rating. Cantor Fitzgerald cut its target price to $125.

Simultaneously, the broader semiconductor sector experienced heavy selling pressure. Within the sector, Micron Technology fell 7.4%, Advanced Micro Devices fell 6.11%, SK hynix fell 4.98%, Taiwan Semiconductor Manufacturing fell 2.45%, and NVIDIA fell 0.77%, as the market reassessed AI infrastructure investment return efficiency.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10